Company intelligence / Profile preview

Invasight

Zurich, Zurich, Switzerlandprevious.sip-baselarea.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Invasight is a Swiss pre-clinical stage biotech company developing first-in-class small molecule protein-protein interaction inhibitors targeting non-traditional intracellular proteins that drive cancer cell invasion. Their lead candidate, F2i, inhibits pro-invasive FGFR signalling and has demonstrated in vivo efficacy in gastric, ovarian, and colorectal cancer models. The ACINDA platform enables rapid identification and design of these inhibitors with improved accuracy and potential for lower clinical failure rates[2][3][5].

Therapeutic areas: Oncology
Modalities: Small moleculeProtein-protein interaction inhibitor
Industry: Biotech

Drug pipeline

1 asset

F2i

Preclinical

Beyond the preview

Go deeper on Invasight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Invasight.

Explore the full profile